Sunday 18 October 2026
Export UNCY’s income statement to Excel — free account
Unicycive Therapeutics, Inc.
UNCY Healthcare Biotechnology
Unicycive Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $675,000.00, down 29.0% from fiscal 2022. In the quarter to June 2026, EPS grew 88.5% and free cash flow grew 9.77%, each against the same quarter a year earlier.
3.36
0.23
−6.41%
Follow UNCY
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | 0.00 | 0.00 | — | — |
Altman Z-Score |
— | — | — | — | — | (36.48) | (10.79) | — | — |
P/S ratio |
— | — | — | — | — | 0.00 | 0.00 | — | — |
P/FCF ratio |
— | — | — | — | — | 0.00 | 0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | (84.02) | (26.80) | — | — |
P/Operating CF |
— | — | — | — | — | (1.24) | (4.90) | — | — |
P/B ratio |
— | — | — | — | — | 0.00 | 0.00 | — | — |
Price to Tangible BV |
— | — | — | — | — | 0.00 | 0.00 | — | — |
EV/Sales |
— | — | — | — | — | 0.00 | 0.00 | — | — |
EV/EBITDA |
— | — | — | — | — | 0.00 | 0.00 | — | — |
EV/Operating CF |
— | — | — | — | — | (0.46) | (0.66) | — | — |
EV/FCF |
— | — | — | — | — | (0.46) | (0.66) | — | — |
Quick Ratio |
— | 0.02 | 0.02 | 0.00 | 7.88 | 0.14 | 0.55 | 1.08 | 2.18 |
Current Ratio |
— | 0.02 | 0.02 | 0.07 | 8.75 | 0.81 | 0.76 | 1.28 | 2.59 |
Net Debt/EBITDA |
— | (1.07) | (0.24) | (0.54) | 1.96 | 0.03 | 0.47 | 0.83 | 1.43 |
Debt/Assets |
0.00% | 3,610.34% | 2,421.05% | 483.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | (0.87) | (0.52) | (0.37) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.08 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.69 | 0.54 | 0.64 | 0.58 | 0.87 | 0.58 | 0.76 | 1.18 |
Capex/Depreciation |
— | — | 0.00 | 0.00 | (0.06) | (0.01) | (0.04) | (0.17) | (0.04) |
Interest Coverage |
— | (11.33) | (14.12) | (8.28) | (14.29) | (3,008.67) | (253.34) | (452.35) | (415.73) |
| — | 0.00% | 207.18% | 127.37% | (145.04%) | (225.47%) | 1,469.52% | (2,088.57%) | (141.14%) | |
| — | (7,724.14%) | (9,020.83%) | (2,030.49%) | (105.73%) | (167.50%) | (369.35%) | (164.96%) | (65.73%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 92.87% | 244.91% | 84.76% | (61.33%) | 2,922.01% | 764.44% | (547.94%) | (88.25%) |
Average Days of Receivables |
— | — | — | — | — | 0.00 | 0.00 | — | — |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 1,307.68% | 1,911.41% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 690.54% | 1,266.22% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 110.09% | 261.78% | 0.00% | 0.00% |
Graham Net Nets |
— | — | — | — | — | (0.08) | (0.21) | — | — |
Graham Number |
— | — | — | — | — | 9.14 | 23.27 | — | — |
Earnings Yield |
— | — | — | — | — | (240.00%) | (174.94%) | — | — |
Free Cash Flow Yield |
— | — | — | — | — | (207.92%) | (84.15%) | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.63 | 0.28 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.05) | (1.45) | (1.72) | (4.94) | (10.39) | (7.45) | (4.27) | (1.97) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | (0.02) | 0.00 | 0.00 | (0.01) | 0.00 |
Free Cash Flow per Share |
— | (0.05) | (1.45) | (1.72) | (4.96) | (10.40) | (7.46) | (4.28) | (1.97) |
Cash per Share |
— | 0.00 | 0.02 | 0.00 | 14.20 | 0.30 | 3.95 | 3.90 | 2.60 |
Shareholders Equity per Share |
— | (0.08) | (1.09) | (3.14) | 14.12 | (0.31) | (1.55) | 1.11 | 1.90 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (0.08) | (1.09) | (3.14) | 14.12 | (0.31) | (1.55) | 1.11 | 1.90 |
Free Cash Flow |
— | (0.77) | (1.18) | (1.46) | (5.80) | (15.65) | (18.29) | (28.65) | (31.34) |
Working Capital |
— | (1.21) | (0.88) | (2.67) | 16.31 | (0.64) | (4.13) | 6.83 | 30.02 |
Capital Expenditures |
— | — | — | — | (0.03) | 0.00 | (0.01) | (0.07) | (0.02) |
Net Current Asset Value |
— | (1.21) | (0.88) | (2.67) | 16.15 | (0.64) | (4.60) | 6.71 | 30.02 |
EV/EBIT |
— | — | — | — | — | 0.00 | 0.00 | — | — |
Capex to Sales |
— | — | — | — | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | — | — | 0.00 | 0.00 | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | — | 0.00 | 0.00 | 17.89 | 7.32 | 10.92 | 5.71 | 8.67 |
Cash ROIC |
— | 578.36% | 287.53% | 86.59% | (17.53%) | 142,300.00% | (310.51%) | (85.33%) | (43.85%) |
Accounts Receivable Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — |
Accounts Payable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Average Payables |
— | — | 0.19 | 0.25 | 0.46 | 0.82 | 0.87 | 0.95 | 0.72 |
Average Assets |
— | 0.01 | 0.02 | 0.11 | 9.47 | 10.78 | 8.50 | 22.93 | 40.40 |
Average Common Equity |
— | — | (1.04) | (1.78) | 6.91 | 8.01 | (2.14) | 1.81 | 18.81 |
Columns are period end dates